|
|
|
|
|
Moake JL. Thrombotic microangiopathies. N Engl J Med.
2002;347:589-600. Review |
|
|
Torok
TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic
thrombocytopenic purpura in the United States - analysis
of national mortality data, 1968-1991. Am J Hematol. 1995
Oct;50(2):84-90 |
|
|
Willis
MS, Bandarenko N. Relapse of thrombotic thrombocytopenic
purpura: is it a continuum of disease? Semin Thromb Hemost.
2005;31:700-8 |
|
|
Sadler
JE, Moake JL, Miyata T, George JN.Recent advances in thrombotic
thrombocytopenic purpura. Hematology Am Soc Hematol Educ
Program. 2004;1:407-23 |
|
|
George
JN. How I treat patients with thrombotic thrombocytopenic
purpura-hemolytic uremic syndrome. Blood. 2000;96:1223-96.
Shumak KH et al Ann Int Med 1995 |
|
|
Shumak
KH, Rock GA, Nair RC. Late relapses in patients successfully
treated for thrombotic thrombocytopenic purpura. Canadian
Apheresis Group. Ann Int Med 1995;122:569-72 |
|
|
Bandarenko
N, Brecher ME. United States Thrombotic Thrombocytopenic
Purpura Apheresis Study Group (US TTP ASG): multicenter
survey and retrospective analysis of current efficacy
of therapeutic plasma exchange. J Clin Apher. 1998;13:133-41 |
|
|
Moschcowitz
E. Hyaline thrombosis of the terminal arterioles and capillaries:
a hitherto undescribed disease. Proc N Y Pathol Soc 1924;
24:21-4 |
|
|
Moake JL,
Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar
J, Seder RH, Hong SL, Deykin D. Unusually large plasma
factor VIII:von Willebrand factor multimers in chronic
relapsing thrombotic thrombocytopenic purpura. N Engl
J Med.1982;307:1432-5 |
|
|
Furlan
M, Robles R, Lammle B. Partial purification and characterization
of a protease from human plasma cleaving von Willebrand
factor to fragments produced by in vivo proteolysis. Blood.
1996;87:4223-34 |
|
|
Tsai HM.
Physiologic cleavage of von Willebrand factor by a plasma
protease is dependent on its conformation and requires
calcium ion. Blood. 1996;87:4235-44 |
|
|
Furlan
M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner
B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler
M, Lammle B. von Willebrand factor-cleaving protease in
thrombotic thrombocytopenic purpura and the hemolytic-uremic
syndrome. N Engl J Med. 1998;339:1578-84 |
|
|
Tsai HM,
Lian EC. Antibodies to von Willebrand factor-cleaving
protease in acute thrombotic thrombocytopenic purpura.
N Engl J Med. 1998 ;339:1585-94 |
|
|
Fujikawa
K, Suzuki H, McMullen B, Chung D. Purification of human
von Willebrand factor-cleaving protease and its identification
as a new member of the metalloproteinase family. Blood.
2001;98:1662-6 |
|
|
Gerritsen
HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence
of purified von Willebrand factor-cleaving protease. Blood.
2001;98:1654-61 |
|
|
Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE,
Fujikawa K. Structure of von Willebrand factor-cleaving
protease (ADAMTS13), a metalloprotease involved in thrombotic
thrombocytopenic purpura. J Biol Chem. 2001;276 :41059-63 |
|
|
Levy
GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee
BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode
R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira
EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a
member of the ADAMTS gene family cause thrombotic thrombocytopenic
purpura. Nature 2001;413:488-94 |
|
|
Padilla
A, Moake JL, Bernardo A, Ball C, Wang Y, Arya M, Nolasco
L, Turner N, Berndt MC, Anvari B, Lopez JA, Dong JF. P-selectin
anchors newly released ultralarge von Willebrand factor
multimers to the endothelial cell surface. Blood. 2004;
103:2150-6 |
|
|
Dong
JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton
CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA. ADAMTS-13
rapidly cleaves newly secreted ultralarge von Willebrand
factor multimers on the endothelial surface under flowing
conditions. Blood. 2002 ;100:4033-9 |
|
|
Dong
JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco
L, Lopez JA, Cruz MA. ADAMTS-13 metalloprotease interacts
with the endothelial cell-derived ultra-large von Willebrand
factor. J Biol Chem. 2003; 278:29633-9 |
|
|
Schulman
I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis.
I. A factor in normal human plasma required for platelet
production; chronic thrombocytopenia due to its deficiency.
Blood 1960;16:943-57 |
|
|
Upshaw
JD. Congenital deficiency of a factor in normal plasma
that reverses microangiopathic hemolysis and thrombocytopenia.
N Engl J Med. 1978;298:1350-2; 10 |
|
|
Tsai HM,
Li A, Rock G. Inhibitors of von Willebrand factor-cleaving
protease in thrombotic thrombocytopenic purpura. Clin
Lab. 2001;47:387-392. |
|
|
Rieger
M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies
in patients with thrombotic microangiopathies and other
immunomediated diseases. Blood. 2005;106:1262-1267. |
|
|
Tsai HM,
Raoufi M, Zhou W, et al. ADAMTS13-binding IgG are present
in patients with thrombotic thrombocytopenic purpura.
Thromb Haemost. 2006;95:886-892. |
|
|
Shelat
SGP, Smith J, Zheng XL. Inhibitory antibodies against
ADAMTS-13 in patients with thrombotic thrombocytopenic
purpura bind ADAMTS-13 protease and may accelarate its
clearance in vivo. J Thromb Haemost. 2006;4:1707-1717. |
|
|
Medina
PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic
purpura- hemolytic uremic syndrome. Curr Opin hematol
2001;8: 286-93 |
|
|
Chiurchiu
C, Ruggenenti P, Remuzzi G. Thrombotic microangiopathy
in renal transplantation. Ann Transplant 2002;7: 28-33 |
|
|
Pettitt
AR, Clarck RE. Thrombotic mycroangiopathy following bone
marrow transplantation. Bone Marrow Transplant 1994; 14:
495-504 |
|
|
Neame PB.
Immunologic and other factors in thrombotic thrombocytopenic
purpura (TTP). Semin Thromb Hemost 1980;6:416-29 |
|
|
Sadler
JE. Thrombotic thrombocytopenic purpura: a moving target.
Hematology Am Soc Hematol Educ Program. 2006;415-20 |
|
|
Remuzzi
G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin
E, Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico
N, Mannucci PM; Italian Registry of Recurrent and Familial
HUS/TTP. Thrombotic thrombocytopenic purpura/hemolytic
uremic syndrome. von Willebrand factor cleaving protease
(ADAMTS13) is deficient in recurrent and familial thrombotic
thrombocytopenic purpura and hemolytic uremic syndrome.
Blood. 2002;100:778-85 |
|
|
George
JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic
Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry:
a community perspective of patients with clinically diagnosed
TTP-HUS. Semin Hematol. 2004;41:60-7 |
|
|
Coppo
P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA,
Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L,
Durey-Dragon MA, Fremeaux-Bacchi V, Ramakers M, Pruna
A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant
JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued
K; Reseau d'Etude des Microangiopathies Thrombotiques
de l'Adulte. Severe ADAMTS13 deficiency in adult idiopathic
thrombotic microangiopathies defines a subset of patients
characterized by various autoimmune manifestations, lower
platelet count, and mild renal involvement. Medicine (Baltimore)
2004;83:233-44 |
|
|
Peyvandi
F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM.
von Willebrand factor cleaving protease (ADAMTS-13) and
ADAMTS-13 neutralizing autoantibodies in 100 patients
with thrombotic thrombocytopenic purpura. Br J Haematol.
2004;127:433-9 |
|
|
Veyradier
A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D,
Girma JP. Ten candidate ADAMTS13 mutations in six French
families with congenital thrombotic thrombocytopenic purpura
(Upshaw-Schulman syndrome). J Thromb Haemost. 2004;2:424-9 |
|
|
Furlan
M, Lammle B. Aetiology and pathogenesis of thrombotic
thrombocytopenic purpura and haemolytic uraemic syndrome:
the role of von Willebrand factor-cleaving protease. Best
Pract Res Clin Haematol. 2001;14:437-54 |
|
|
Elliott
MA, Nichols WL. Thrombocytopenic purpura and hemolytic
uremic sindrome. Mayo Clin Prot 2001;76:1154 -1162 |
|
|
Chang
JC, Kathula SK. Various clinical manifestation in patients
with thrombotic microangiopahty. Journal of Investigative
Medicine 2002;50:201-6 |
|
|
Rock GA,
Shumak KM, Buskard NA, Blanchette VS, Kelton JG, Nair
RC, and Spasoff RA. Comparison of plasma exchange with
plasma infusion in the treatment of thrombotic thrombocytopenic
purpura. Canadian Apheresis Study Group. N Engl J Med
1991; 325: 393-7 |
|
|
Guideline
of the diagnosis and management of thrombotic microangiopathic
haemolytic anemias. British Journal of Hematology 2003;
120: 556-573 |
|
|
Bell WR,
Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic
thrombocytopenic purpura-hemolytic uremic syndrome. Clinical
experience in 108 patiens. N Engl J Med 1991;325: 398-403 |
|
|
Dervenoulas
J, Tsirigotis P, Bollas G, Koumarianou AA, Pappa V, Mantzios
G, Xiros N, Economopoulos T, Papageorgiou E, Pappa M,
Raptis SA. Efficacy of intravenous immunoglobulin in the
treatment of thrombotic thrombocytopaenic purpura. A study
of 44 cases. Acta Haematol 2001;105:204-8 |
|
|
Crowther
MA, Heddle N, Hayward CP, Warkentin T, Kelton JG. Splenectomy
done during hematologic remission to prevent relapse in
patients with thrombotic thrombocytopenic purpura. Ann
Intern Med 1996; 125:294-6 |
|
|
Allan
DS, Kovasc Mj, Clark WF. Frequently relapsing thrombotic
thrombocytopenic purpura treated with cytotoxic immunosuppressive
therapy. Haematologica 2001; 86:844-50 |
|
|
Zheng
X, Pallera AM, Goodnough LT. Remission of chronic thrombocytopenic
purpura after treatment with cyclophosphamide and rituximab
Ann Intern Med 2003;138:105-108 |
|
|
George
JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab
therapy for thrombotic thrombocytopenic purpura: a proposed
study of the Transfusion Medicine/Hemostasis Clinical
Trials Network with a systematic review of rituximab therapy
for immune-mediated disorders. J Clin Apher. 2006;21:49-56 |
|
|
Donadelli
R, Banterla F, Galbusera M, Capoferri C, Bucchioni S,
Gastoldi S, Nosari S, Monteferrante G, Ruggeri ZM, Bresin
E, Scheiflinger F, Rossi E, Martinez C, Coppo R, Remuzzi
G, Noris M; on behalf of the International Registry of
Recurrent and Familial HUS/TTP. In-vitro and in-vivo consequences
of mutations in the von Willebrand factor cleaving protease
ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb
Haemost. 2006;96:454-64 |
|
|
Antoine
G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD,
Lammle B, Scheiflinger F. ADAMTS13 gene defects in two
brothers with constitutional thrombotic thrombocytopenic
purpura and normalization of von Willebrand factor-cleaving
protease activity by recombinant human ADAMTS13. Br J
Haematol. 2003;120:821-4 |
|
|
Veyradier
A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D,
Girma JP. Ten candidate ADAMTS13 mutations in six French
families with congenital thrombotic thrombocytopenic purpura
(Upshaw-Schulman syndrome). J Thromb Haemost. 2004;2:424-9 |
|
|
Bestetti
G, Stellari A, Lattuada A, Corbellino M, Parravicini C,
Calzarossa C, Cenzuales S, Moroni M, Galli M, Rossi E.
ADAMTS 13 genotype and vWF protease activity in an Italian
family with TTP. Thromb Haemost. 2003;90:955-6 |
|
|
Matsumoto
M, Kokame K, Soejima K, Miura M, Hayashi S, Fujii Y, Iwai
A, Ito E, Tsuji Y, Takeda-Shitaka M, Iwadate M, Umeyama
H, Yagi H, Ishizashi H, Banno F, Nakagaki T, Miyata T,
Fujimura Y. Molecular characterization of ADAMTS13 gene
mutations in Japanese patients with Upshaw-Schulman syndrome.Blood
2004;103:1305-10 |
|
|
Studt
JD, Hovinga JA, Radonic R, Gasparovic V, Ivanovic D, Merkler
M, Wirthmueller U, Dahinden C, Furlan M, Lammle B. Familial
acquired thrombotic thrombocytopenic purpura: ADAMTS13
inhibitory autoantibodies in identical twins. Blood 2004;103:4195-7 |
|
|
Schneppenheim
R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, Hassenpflug
W, Haberle J, Kentouche K, Kohne E, Kurnik K, Mueller-Wiefel
D, Obser T, Santer R, Sykora KW. von Willebrand factor
cleaving protease and ADAMTS13 mutations in childhood
TTP. Blood 2003;101:1845-50 |
|
|
Shibagaki
Y, Matsumoto M, Kokame K, Ohba S, Miyata T, Fujimura Y,
Fujita T. Novel compound heterozygote mutations (H234Q/R1206X)
of the ADAMTS13 gene in an adult patient with Upshaw-Schulman
syndrome showing predominant episodes of repeated acute
renal failure.
Nephrol Dial Transplant. 2006;21:1289-92 |
|
|
Assink
K, Schiphorst R, Allford S, Karpman D, Etzioni A, Brichard
B, van de Kar N, Monnens L, van den Heuvel L. Mutation
analysis and clinical implications of von Willebrand factor-cleaving
protease deficiency. Kidney Int. 2003;63:1995-9 |
|
|
Uchida
T, Wada H, Mizutani M, Iwashita M, Ishihara H, Shibano
T, Suzuki M, Matsubara Y, Soejima K, Matsumoto M, Fujimura
Y, Ikeda Y, Murata M; Research Project on Genetics of
Thrombosis. Identification of novel mutations in ADAMTS13
in an adult patient with congenital thrombotic thrombocytopenic
purpura. Blood. 2004;104:2081-3 |
|
|
Kokame
K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato
M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura
Y. Mutations and common polymorphisms in ADAMTS13 gene
responsible for von Willebrand factor-cleaving protease
activity. Proc Natl Acad Sci U S A. 2002;99:11902-7 |
|
|
Schneppenheim
R, Kremer Hovinga JA, Becker T, Budde U, Karpman D, Brockhaus
W, Hrachovinova I, Korczowski B, Oyen F, Rittich S, von
Rosen J, Tjonnfjord GE, Pimanda JE, Wienker TF, Lammle
B. A common origin of the 4143insA ADAMTS13 mutation.
Thromb Haemost. 2006;96:3-6 |
|
|
Tao Z,
Anthony K, Pen ‚Y, Choi H, Nolasco L, Rice L, Moake
JL, Dong JF. Novel ADAMTS 13 mutations in an adult with
delayed onset thrombotic thrombocytopenic purpura. J Thromb
Haemost. 2006;4:1931-5 |
|
|
Licht
C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe
B. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic
purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int.
2004;66:955-8 |
|
|
Savasan
S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation
in congenital thrombotic thrombocytopenic purpura with
previously reported normal VWF cleaving protease activity.
Blood. 2003;101:4449-51 |
|
|
Peyvandi
F, Lavoretano S, Palla R, Valsecchi C, Merati G, De Cristofaro
R, Rossi E, Mannuccio Mannucci P. Mechanisms of the interaction
between two ADAMTS13 gene mutations leading to severe
deficiency of enzymatic activity. Hum Mutat. 2006;27:330-6 |
| |
|
 |
|
|
